Astellas broke into the neurology market through our partnership with Zogenix on SUMAVEL^TM DosePro^TM, and we're here to stay. We realize the unmet medical needs of patients, specifically the 30 million Americans who suffer from migraines. At Astellas, neurology research is identified as a top R&D focus area because of the high needs of patients and the research potential in this category. We are committed to neurology so we can truly continue to make a difference in the lives of patients.

This information is intended for U.S. residents only.

SUMAVEL and DosePro are trademarks of Zogenix, Inc. SUMAVEL^TM DosePro^TM is co-promoted with Astellas Pharma U.S., Inc. in the U.S.